Literature DB >> 33783995

Androgen receptor decreases renal cell carcinoma bone metastases via suppressing the osteolytic formation through altering a novel circEXOC7 regulatory axis.

Dongkui Gong1,2, Yin Sun2, Changcheng Guo2,3, Tzong-Jen Sheu4, Wei Zhai2,5, Junhua Zheng6, Chawnshang Chang2,7.   

Abstract

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) has gender differences, with the androgen receptor (AR) linked positively with metastasis to the lung. Its linkage to ccRCC bone metastases (RBMs), however, remains unclear.
METHODS: In the current study, five human RCC and five RCC bone metastasis tissues were deeply sequenced using Arraystar human circRNA V2.0 microarray. We conducted gain-of-function screening in vitro and in vivo to elucidate the AR's role in the RBM. Loss/gain-of-function was also implemented to verify the roles of related non-coding RNAs and proteins.
RESULTS: We uncovered that RBM also has a gender difference showing higher AR expression may be linked to fewer RBMs, which might involve suppressing osteolytic formation. Mechanism dissection indicates that AR can decrease the circular RNA EXOC7 (circEXOC7), expression via enhancing transcription of DHX9, a regulatory protein in circRNA biogenesis. The circEXOC7 can sponge/suppress miR-149-3p resulting in suppressing the CSF1 expression by directly binding to the 3'UTR region of CSF1 mRNA. Results from clinical epidemiological surveys also found that AR has a positive correlation with miR-149-3p and a negative correlation with CSF1 in AR-positive ccRCC tissues. Preclinical studies with Balb/c nude mouse model also validated that targeting this newly verified AR/DHX9/circEXOC7/miR-149-3p/CSF1 signaling via altering circEXOC7 or AR could lead to suppressing the RBM progression.
CONCLUSIONS: These data showed that AR/DHX9/circEXOC7/miR-149-3p/CSF1 signaling acts as a valuable feature in the bone metastasis of renal cancer, which may benefit in suppressing the RBM progression.
© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Entities:  

Keywords:  CSF1; DHX9; androgen receptor; bone metastases; ccRCC; circEXOC7; miR-149-3p

Mesh:

Substances:

Year:  2021        PMID: 33783995      PMCID: PMC7989709          DOI: 10.1002/ctm2.353

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN: 2001-1326


  55 in total

1.  Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p.

Authors:  Chang Hoon Shin; Hong Lee; Hye Ree Kim; Kyung Hee Choi; Je-Gun Joung; Hyeon Ho Kim
Journal:  Cell Death Differ       Date:  2017-07-14       Impact factor: 15.828

2.  Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases.

Authors:  Sylvain Contié; Nathalie Voorzanger-Rousselot; Judith Litvin; Philippe Clézardin; Patrick Garnero
Journal:  Int J Cancer       Date:  2010-10-13       Impact factor: 7.396

3.  Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.

Authors:  M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz
Journal:  Ann Oncol       Date:  2011-09-02       Impact factor: 32.976

Review 4.  Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.

Authors:  Haris Zahoor; Brian I Rini
Journal:  Expert Opin Emerg Drugs       Date:  2016-10-12       Impact factor: 4.191

5.  Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.

Authors:  W Zhai; Y Sun; M Jiang; M Wang; T A Gasiewicz; J Zheng; C Chang
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

6.  Tumor cell survival dependence on the DHX9 DExH-box helicase.

Authors:  T Lee; M Paquet; O Larsson; J Pelletier
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

7.  LINC00470 Coordinates the Epigenetic Regulation of ELFN2 to Distract GBM Cell Autophagy.

Authors:  Changhong Liu; Haijuan Fu; Xiaoping Liu; Qianqian Lei; Yan Zhang; Xiaoling She; Qiang Liu; Qing Liu; Yingnan Sun; Guiyuan Li; Minghua Wu
Journal:  Mol Ther       Date:  2018-06-27       Impact factor: 11.454

8.  Bone protection by inhibition of microRNA-182.

Authors:  Kazuki Inoue; Zhonghao Deng; Yufan Chen; Eugenia Giannopoulou; Ren Xu; Shiaoching Gong; Matthew B Greenblatt; Lingegowda S Mangala; Gabriel Lopez-Berestein; David G Kirsch; Anil K Sood; Liang Zhao; Baohong Zhao
Journal:  Nat Commun       Date:  2018-10-05       Impact factor: 14.919

Review 9.  An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.

Authors:  Viktor Grünwald; Berit Eberhardt; Axel Bex; Anne Flörcken; Thomas Gauler; Thorsten Derlin; Martin Panzica; Hans Roland Dürr; Knut Achim Grötz; Rachel H Giles; Christian von Falck; Anno Graser; Alexander Muacevic; Michael Staehler
Journal:  Nat Rev Urol       Date:  2018-08       Impact factor: 14.432

10.  Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.

Authors:  Hangchuan Shi; Yin Sun; Miao He; Xiong Yang; Michiaki Hamada; Tsukasa Fukunaga; Xiaoping Zhang; Chawnshang Chang
Journal:  Oncogene       Date:  2019-09-09       Impact factor: 9.867

View more
  9 in total

Review 1.  Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma.

Authors:  Rebeca Osca-Verdegal; Jesús Beltrán-García; José Luis Górriz; José María Martínez Jabaloyas; Federico V Pallardó; José Luis García-Giménez
Journal:  Front Cell Dev Biol       Date:  2022-06-22

2.  Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway.

Authors:  Zhipeng Xu; Shuqiu Chen; Ruiji Liu; Hui Chen; Bin Xu; Weizhang Xu; Ming Chen
Journal:  Mol Cancer       Date:  2022-07-15       Impact factor: 41.444

3.  The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer.

Authors:  Lidia Chellini; Marco Pieraccioli; Claudio Sette; Maria Paola Paronetto
Journal:  J Exp Clin Cancer Res       Date:  2022-05-19

4.  External Validation of the Prognostic Value of an Immune-Associated Gene Panel for Clear Cell Renal Cell Carcinomas.

Authors:  Zhiwen Xie; Lei Wu; Shan Hua; Yongqing Zhang; Fei Shi; Min Chen; Sheng Zhao; Zhihong Liu; Meng Liu; Juntao Jiang
Journal:  Front Cell Dev Biol       Date:  2021-12-23

5.  Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells.

Authors:  So-Yeon Park; Jee-Heun Kim; Jang-Hyun Choi; Choong-Jae Lee; Won-Jae Lee; Sehoon Park; Zee-Yong Park; Jeong-Heum Baek; Jeong-Seok Nam
Journal:  Clin Transl Med       Date:  2021-11

Review 6.  Interaction between Non-Coding RNAs and Androgen Receptor with an Especial Focus on Prostate Cancer.

Authors:  Mohammad Taheri; Tayyebeh Khoshbakht; Elena Jamali; Julia Kallenbach; Soudeh Ghafouri-Fard; Aria Baniahmad
Journal:  Cells       Date:  2021-11-16       Impact factor: 6.600

7.  Hsa_circRNA_0088036 acts as a ceRNA to promote bladder cancer progression by sponging miR-140-3p.

Authors:  Jun Yang; Manlong Qi; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Cell Death Dis       Date:  2022-04-08       Impact factor: 8.469

8.  Development and Validation of a Predictive Model to Evaluate the Risk of Bone Metastasis in Kidney Cancer.

Authors:  Shengtao Dong; Hua Yang; Zhi-Ri Tang; Yuqi Ke; Haosheng Wang; Wenle Li; Kang Tian
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

9.  Risk Factors, Prognostic Factors, and Nomograms for Bone Metastasis in Patients with Newly Diagnosed Clear Cell Renal Cell Carcinoma: A Large Population-Based Study.

Authors:  Hongmin Zhou; Sheng Yang; Tiancheng Xie; Longfei Wang; Sen Zhong; Tianyang Sheng; Guoxin Fan; Xiang Liao; Yunfei Xu
Journal:  Front Surg       Date:  2022-04-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.